Table 2 Demographic and clinical characterstics, laboratory test results and outcome data in the three clinical subgroups of MIS-C patients based on the leading clinical symptoms at the first visit

Demographic and clinical characteristics at admission, n (%)

Age in years, median (min.-max.)

6 (3–10)

9 (3–17)

6 (19 months − 15 years)

0.49

Male sex

11 (44%)

11 (64.7%)

10 (90.9%)

0.027

Comorbidities, n (%)

4 (16%)

3 (17.6%)

4 (36.4%)

0.97

Fever, days at admission, median

6

5

4

0.144

Gastrointestinal symptoms

19 (76%)

13 (76.5%)

6 (54.5%)

0.09

Mucocutaneous symptoms

25 (100%)

12 (70.6%)

2 (18.2%)

< 0.001

Cardiovascular symptoms

14 (56%)

13 76.5%)

3 (27.3%)

0.078

Respiratory symptoms

8 (32%)

6 (35.3%)

5 (45.5%)

0.333

Neurological symptoms

1 (4%)

2 (11.8%)

2 (18.2%)

0.547

Renal symptoms

1 (4%)

6 (35.3%)

4 (36.4%)

0.030

SARS-CoV-2 test results, n (%)

Positive RT-PCR

4 (16%)

4 (23.5%)

4 (36.4%)

0.093

Positive serology

21/24 (87.5%)

12 (70.6%)

9 (81.8%)

0.198

Laboratory confirmed SARS-CoV-2 infection

24 (96%)

13 (76.5%)

10 (90.9%)

0.091

Epidemiological link to confirmSARS-CoV-2 infection

11 (44%)

6 (35.3%)

3 (27.3%)

0.386

Cardiogical disorders, n (%)

Myocardial dysfunction

6 (24%)

11 (64.7%)

0

0.037

Coronary artery abnormalities

3 (12%)

1 (5.9%)

1 (9.1%)

0.80

Coronary artery aneurysm

0

0

0

N.A.

Mitral valve regurgitation

10 (25%)

4 (23.5%)

0

0.151

Pericardial effusion

4 (16%)

4 (23.5%)

1 (9.1%)

0.933

Abnormal ECG

7 (28%)

9 (52.9%)

0

0.182

Laboratory test at admission (normal range), median (IQR), % of aberrant values

Platelets (150–400 Giga/L)

236 (128–330)

52.00%

216 (122–274)

47.06%

275 (250–347)

18.18%

0.683

WBC count (4.5–11.5 Giga/L)

12.84 (9.23–17.15)

68.00%

12 (9.71–14.43)

58.82%

11.31 (9.16–16.87)

36.36%

0.969

Absolute lymphocyte count (0.9-4 Giga/L)

1.395 (0.95–2.84)

36.00%

1.28 (0.9–1.75)

29.41%

2.32 (1.69–3.21)

9.09%

0.185

 C-reactive protein (< 2.2 mg/L)

186.16 (133.21-243.13)

100.00%

174.12 (115,8-205)

100.00%

43 (28.73-139.14)

90.91%

0.003

PCT (< 0.5 ug/L)

1.91 (0.7–3.77)

80.00%

2.6 (0.87–8.09)

88.24%

0.9 (0.2–2.3)

45.45%

0.272

Interleukin-6 (< 7 ng/L)

211.4 (124.1-358.37)

100.00%

144.95 (51.52–299.5)

94.12%

100.21 (22.89-215.05)

72.73%

0.504

Cardiac TnT (< 10 ng/L)

23.21 (19.05–49.98)

60.00%

21.175 (14.13–59.79)

82.35%

29.3 (19.24–50.42)

63.64%

0.431

Pro-BNP (< 191.1 ng/L) < 191,1

1634.74 (829.8-7590.16)

80.00%

2909 (2400.94-1045.88)

88.24%

3016.61 (678.17-6425.63)

63.64%

0.803

Ferritin (13–150 ug/L)

396.2 (262.05-642.75)

80.00%

559.8 (385.9-703.6)

100.00%

188.3 (124.8-356.1)

45.45%

0.147

INR

1.03 (0.96–1.11)

N/A

1.06 (0.97–1.11)

N/A

1.04 (0.98–1.08)

N/A

0.248

D-dimer (< 0.5 mg FEU/L)

2.42 (1.53–3.84)

88.00%

3.58 (1.7–6.44)

100.00%

1.89 (0.7–3.62)

90.91%

0.258

Albumin (35–52 g/L)

34 (30–38)

44.00%

32.5 (28.75–35.25)

58.82%

36 (34–38)

27.27%

0.307

Urea (1.4–6.8 mmol/L)

4.55 (3.7–7.4)

24.00%

5.15 (3.77–8.02)

29.41%

3.8 (2.55–4.55)

0.00%

0.072

Creatinine (26–88 umol/L)

39.5 (33-52.75)

4.00%

48.5 (37-72.5)

17.65%

40 (28.5–52.5)

0.00%

0.144

GPT (< 40 U/L)

28 (19–60)

24.00%

23 (14-39.75)

23.53%

14 (12-18.5)

0.00%

0.335

Bicarbonate (24 mmol/L)

24.45 (22.97–25.5)

8.00%

25.75 (23.55–27.9)

17.65%

24.1 (22.17–25.92)

18.18%

0.476

Clinical outcome, n (%)

Days of pediatric intensive care unit (median)

0

4

0

 N/A

Oxygen therapy

4 (16%)

3 (17.6%)

1 (9.1%)

0.97

Non-invasive respiratory support

0

2 (11.8%)

1 (9.1%)

0.1106

Invasive mechanical ventilation

0

1 (5.9%)

0

0.16

Vasoactive drugs

6 (24%)

12 (70.6%)

0

0.049

Death

0

0

0

N/A